Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, L.go A. Gemelli, 8 - 00168, Rome, Italy.
Neurosurgical Clinic, AOUP Paolo Giaccone, Department of Biomedicine Neurosciences and Advanced Diagnostics, School of Medicine, University of Palermo, Palermo, Italy.
Neurosurg Rev. 2022 Aug;45(4):2837-2844. doi: 10.1007/s10143-022-01799-z. Epub 2022 May 3.
In case of subarachnoid hemorrhage (SAH) associated with multiple intracranial aneurysms (MIAs), the main goal of acute treatment is securing the source of bleeding (index aneurysm). Indications and timing of bystanders treatment are instead still debated as the risk of new SAHs in patients harboring MIAs is not yet established. However, even if technically feasible, a simultaneous management of all aneurysms remains questionable, especially for safety issues. We retrospectively reviewed our last 5-year experience with SAH patients harboring MIAs entered in a clinic-radiological monitoring for bystanders follow-up in order to evaluate the occurrence of morphological changes, bleeding events, and safety and efficacy of a delayed treatment. We included 39 patients with mean age of 59.5 ± 12.2 years who survived a SAH. Among them, 14 underwent treatment, whereas 25 continued follow-up. The mean time between index and bystanders treatment was 14.3 ± 19.2 months. Patients undergoing bystanders treatment were mainly female and in general younger than patients undergoing observation. No cases of growth or bleeding were observed among bystanders within the two groups during the follow-up, which was longer than 1 year for the intervention group, and almost 40 months for the observation group. No major complications and mRS modifications were observed after bystanders treatment. Our data seem to suggest that within the short follow-up, intervention and observation seem to be likewise safe for bystander aneurysms, showing at the same time that a delayed management presents a similar risk profile of treating unruptured aneurysms in patients with no previous history of SAH.
如果蛛网膜下腔出血(SAH)与多个颅内动脉瘤(MIAs)相关,急性治疗的主要目标是确保出血源(指数动脉瘤)的安全。然而,由于尚未确定存在 MIAs 的患者发生新的 SAH 的风险,旁观者治疗的适应证和时机仍存在争议。但是,即使在技术上可行,同时处理所有动脉瘤仍然存在疑问,特别是出于安全问题的考虑。我们回顾性地分析了过去 5 年在诊所接受影像学监测的 SAH 患者的经验,这些患者因处于旁观者随访中而存在 MIAs,目的是评估形态变化、出血事件的发生情况,以及延迟治疗的安全性和疗效。我们纳入了 39 例平均年龄为 59.5±12.2 岁的 SAH 幸存者。其中 14 例接受了治疗,而 25 例继续进行随访。指数治疗和旁观者治疗之间的平均时间为 14.3±19.2 个月。接受旁观者治疗的患者主要为女性,且一般比接受观察的患者更年轻。在随访期间,两组中均未观察到旁观者动脉瘤的生长或出血。对于干预组,随访时间超过 1 年,而对于观察组,随访时间几乎为 40 个月。旁观者治疗后未观察到严重并发症和 mRS 改变。我们的数据似乎表明,在短期随访中,干预和观察对旁观者动脉瘤同样安全,同时表明,对于没有先前 SAH 病史的患者,延迟治疗未破裂动脉瘤的风险特征相似。